首页 > 最新文献

Pulmonary Medicine最新文献

英文 中文
The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device. ICS/LABA 固定剂量组合在治疗哮喘和慢性阻塞性肺病中的作用:仿制丙酸氟替卡松-沙美特罗装置的生物等效性。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2021-03-17 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8881895
Donald P Tashkin, Jill A Ohar, Arkady Koltun, Richard Allan, Jonathan K Ward

Both asthma and chronic obstructive pulmonary disease (COPD) are inflammatory chronic respiratory conditions with high rates of morbidity and mortality worldwide. The objectives of this review are to briefly describe the pathophysiology and epidemiology of asthma and COPD, discuss guideline recommendations for uncontrolled disease, and review a new generic option for the treatment of asthma and COPD. Although mild forms of these diseases may be controlled with as-needed pharmacotherapy, uncontrolled or persistent asthma and moderate or severe COPD uncontrolled by bronchodilators with elevated eosinophilia or frequent exacerbations may require intervention with combination therapy with inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs), according to international guidelines. Fixed-dose combinations of ICS/LABA are commonly prescribed for both conditions, with fluticasone propionate (FP) and salmeterol forming a cornerstone of many treatment plans. An oral inhalation powder containing the combination of FP and salmeterol has been available as Advair Diskus® in the United States for almost 20 years, and the first and only substitutable generic version of this product has recently been approved for use: Wixela™ Inhub™. Bioequivalence of Wixela Inhub and Advair Diskus has been established. Furthermore, the Inhub inhaler was shown to be robust and easy to use, suggesting that Wixela Inhub may provide an alternative option to Advair Diskus for patients with asthma or COPD requiring intervention with an ICS/LABA.

哮喘和慢性阻塞性肺疾病(COPD)都是炎症性慢性呼吸系统疾病,在全球范围内发病率和死亡率都很高。本综述旨在简要介绍哮喘和慢性阻塞性肺病的病理生理学和流行病学,讨论针对未得到控制的疾病的指南建议,并综述治疗哮喘和慢性阻塞性肺病的一种新的通用方案。虽然这些疾病的轻度症状可以通过按需药物治疗得到控制,但根据国际指南,无法控制或持续存在的哮喘以及无法通过支气管扩张剂控制的中度或重度慢性阻塞性肺疾病,如果伴有嗜酸性粒细胞增多或频繁恶化,则可能需要使用吸入性皮质类固醇(ICS)和长效β受体激动剂(LABAs)联合疗法进行干预。ICS/LABA的固定剂量组合是治疗这两种疾病的常用处方,其中丙酸氟替卡松(FP)和沙美特罗是许多治疗方案的基石。含有氟替卡松和沙美特罗复方制剂的口服吸入粉剂 Advair Diskus® 在美国已上市近 20 年,该产品的首个也是唯一一个可替代的仿制药最近已获准使用:Wixela™ Inhub™。Wixela Inhub 和 Advair Diskus 的生物等效性已经确定。此外,Inhub吸入器被证明坚固耐用且易于使用,这表明对于需要使用ICS/LABA进行干预的哮喘或慢性阻塞性肺病患者来说,Wixela Inhub可作为Advair Diskus的替代选择。
{"title":"The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.","authors":"Donald P Tashkin, Jill A Ohar, Arkady Koltun, Richard Allan, Jonathan K Ward","doi":"10.1155/2021/8881895","DOIUrl":"10.1155/2021/8881895","url":null,"abstract":"<p><p>Both asthma and chronic obstructive pulmonary disease (COPD) are inflammatory chronic respiratory conditions with high rates of morbidity and mortality worldwide. The objectives of this review are to briefly describe the pathophysiology and epidemiology of asthma and COPD, discuss guideline recommendations for uncontrolled disease, and review a new generic option for the treatment of asthma and COPD. Although mild forms of these diseases may be controlled with as-needed pharmacotherapy, uncontrolled or persistent asthma and moderate or severe COPD uncontrolled by bronchodilators with elevated eosinophilia or frequent exacerbations may require intervention with combination therapy with inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs), according to international guidelines. Fixed-dose combinations of ICS/LABA are commonly prescribed for both conditions, with fluticasone propionate (FP) and salmeterol forming a cornerstone of many treatment plans. An oral inhalation powder containing the combination of FP and salmeterol has been available as Advair Diskus® in the United States for almost 20 years, and the first and only substitutable generic version of this product has recently been approved for use: Wixela™ Inhub™. Bioequivalence of Wixela Inhub and Advair Diskus has been established. Furthermore, the Inhub inhaler was shown to be robust and easy to use, suggesting that Wixela Inhub may provide an alternative option to Advair Diskus for patients with asthma or COPD requiring intervention with an ICS/LABA.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2021 ","pages":"8881895"},"PeriodicalIF":2.0,"publicationDate":"2021-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25558799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trainability of Health-Related and Motor Performance Fitness in Adults with Cystic Fibrosis within a 12-Month Partially Supervised Exercise Program. 囊性纤维化成人患者在12个月的部分监督锻炼计划中健康相关和运动性能的可训练性
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2021-03-09 eCollection Date: 2021-01-01 DOI: 10.1155/2021/5581812
Matthias Welsner, Wolfgang Gruber, Uwe Mellies, Margarete Olivier, Sivagurunathan Sutharsan, Christian Taube, Stefanie Dillenhoefer, Cordula Koerner-Rettberg, Florian Stehling

Background: Regular physical activity plays an important role in the treatment of patients with cystic fibrosis (CF). This study is aimed at investigating the effects of a 12-month partially supervised exercise program on attributes of health-related and motor performance fitness, lung function (ppFEV1), BMI, and habitual physical activity (HPA, steps/day) in adults with CF.

Methods: Attributes of health-related and motor performance fitness were examined at the beginning (T0), after 6 (T1), and 12 months (T2) on the basis of five test items: forward bend (FB), bent knee hip extension (HE), plank leg raise (PLR), standing long jump (SLJ), and standing on one leg (OLS). Additionally, we recorded HPA by accelerometry, peak exercise performance (W peak) by an incremental cycle test, ppFEV1, and BMI. During the first six months, there was close supervision by an experienced sport therapist.

Results: 26 CF patients (8 female, mean age 26.5 ± 7.9 years; ppFEV1 53.7 ± 21.0) completed the exercise program. Significant improvements were recorded from T0 to T1 (FB: p ≤ 0.05; PLR, OLS: p ≤ 0.01) and from T0 to T2 (FB, PLR: p ≤ 0.01 and HE, OLS: p ≤ 0.05). W peak, ppFEV1, BMI, and HPA showed no significant improvement between the single test points and over the entire study period (all p > 0.05).

Conclusion: Our results show trainability of adults with CF in aspects of health-related and motor performance fitness during a partially supervised exercise program. Close supervision positively influences the results. Using a simple test setup seems to be a promising tool for evaluating the effects of exercise programs in CF and could serve as an additional outcome parameter in future clinical trials. Trial registration: ClinicalTrials.gov (retrospectively registered May 8, 2018).

背景:规律的体育锻炼在囊性纤维化(CF)患者的治疗中起着重要作用。本研究旨在探讨一项为期12个月的部分监督运动计划对慢性心力衰竭成人健康相关和运动性能指标、肺功能(ppFEV1)、BMI和习惯性体力活动(HPA,步数/天)的影响。方法:在开始(T0)、6 (T1)和12个月(T2)进行健康相关和运动性能指标的检测。前屈(FB),屈膝髋伸(HE),平板抬腿(PLR),立定跳远(SLJ),单腿站立(OLS)。此外,我们通过加速计记录了HPA,通过增量循环测试记录了运动表现峰值(W峰),ppFEV1和BMI。在前六个月,有一位经验丰富的运动治疗师密切监督。结果:CF患者26例(女性8例,平均年龄26.5±7.9岁;ppFEV1(53.7±21.0)完成运动方案。从T0到T1有显著改善(FB: p≤0.05;PLR, OLS: p≤0.01)和T0 ~ T2 (FB, PLR: p≤0.01,HE, OLS: p≤0.05)。W峰、ppFEV1、BMI和HPA在单点和整个研究期间均无显著改善(p > 0.05)。结论:我们的研究结果表明,在部分监督的锻炼计划中,CF成人在健康相关和运动性能方面的可训练性。密切的监督对结果有积极的影响。使用一个简单的测试设置似乎是一个很有前途的工具来评估运动计划对CF的影响,并可以作为未来临床试验的额外结果参数。试验注册:ClinicalTrials.gov(回顾性注册于2018年5月8日)。
{"title":"Trainability of Health-Related and Motor Performance Fitness in Adults with Cystic Fibrosis within a 12-Month Partially Supervised Exercise Program.","authors":"Matthias Welsner,&nbsp;Wolfgang Gruber,&nbsp;Uwe Mellies,&nbsp;Margarete Olivier,&nbsp;Sivagurunathan Sutharsan,&nbsp;Christian Taube,&nbsp;Stefanie Dillenhoefer,&nbsp;Cordula Koerner-Rettberg,&nbsp;Florian Stehling","doi":"10.1155/2021/5581812","DOIUrl":"https://doi.org/10.1155/2021/5581812","url":null,"abstract":"<p><strong>Background: </strong>Regular physical activity plays an important role in the treatment of patients with cystic fibrosis (CF). This study is aimed at investigating the effects of a 12-month partially supervised exercise program on attributes of health-related and motor performance fitness, lung function (ppFEV1), BMI, and habitual physical activity (HPA, steps/day) in adults with CF.</p><p><strong>Methods: </strong>Attributes of health-related and motor performance fitness were examined at the beginning (T0), after 6 (T1), and 12 months (T2) on the basis of five test items: forward bend (FB), bent knee hip extension (HE), plank leg raise (PLR), standing long jump (SLJ), and standing on one leg (OLS). Additionally, we recorded HPA by accelerometry, peak exercise performance (<i>W</i> <sub>peak</sub>) by an incremental cycle test, ppFEV1, and BMI. During the first six months, there was close supervision by an experienced sport therapist.</p><p><strong>Results: </strong>26 CF patients (8 female, mean age 26.5 ± 7.9 years; ppFEV1 53.7 ± 21.0) completed the exercise program. Significant improvements were recorded from T0 to T1 (FB: <i>p</i> ≤ 0.05; PLR, OLS: <i>p</i> ≤ 0.01) and from T0 to T2 (FB, PLR: <i>p</i> ≤ 0.01 and HE, OLS: <i>p</i> ≤ 0.05). <i>W</i> <sub>peak</sub>, ppFEV1, BMI, and HPA showed no significant improvement between the single test points and over the entire study period (all <i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>Our results show trainability of adults with CF in aspects of health-related and motor performance fitness during a partially supervised exercise program. Close supervision positively influences the results. Using a simple test setup seems to be a promising tool for evaluating the effects of exercise programs in CF and could serve as an additional outcome parameter in future clinical trials. Trial registration: ClinicalTrials.gov (retrospectively registered May 8, 2018).</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2021 ","pages":"5581812"},"PeriodicalIF":4.3,"publicationDate":"2021-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7964122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25513678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Effectiveness of Clinical Decision Tools in Predicting Pulmonary Embolism. 临床决策工具预测肺栓塞的有效性。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2021-02-19 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8880893
Michael A Simon, Christopher Tan, Patrick Hilden, Lyle Gesner, Barry Julius

Objective: The Wells criteria and revised Geneva score are two commonly used clinical decision tools (CDTs) developed to assist physicians in determining when computed tomographic angiograms (CTAs) should be performed to evaluate the high index of suspicion for pulmonary embolism (PE). Studies have shown varied accuracy in these CDTs in identifying PE, and we sought to determine their accuracy within our patient population.

Methods: Patients admitted to the Emergency Department (ED) who received a CTA for suspected PE from 2019 Jun 1 to 2019 Aug 31 were identified. Two CDTSs, the Wells criteria and revised Geneva score, were calculated based on data available prior to CTA and using the common D-Dimer cutoff of >500 μg/L. We determined the association between confirmed PE and CDT values and determined the association between the D-Dimer result and PE.

Results: 392 CTAs were identified with 48 (12.1%) positive PE cases. The Wells criteria and revised Geneva score were significantly associated with PE but failed to identify 12.5% and 70.4% of positive PE cases, respectively. Within our cohort, a D-Dimer cutoff of >300 μg/L was significantly associated with PE and captured 95.2% of PE cases.

Conclusions: Both CDTs were significantly associated with PE but failed to identify PE in a significant number of cases, particularly the revised Geneva score. Alternative D-Dimer cutoffs may provide better accuracy in identifying PE cases.

目的:Wells标准和修订后的Geneva评分是两种常用的临床决策工具(CDTs),用于帮助医生确定何时应进行计算机断层血管造影(cta)来评估肺栓塞(PE)的高怀疑指数。研究表明,这些CDTs在鉴别PE方面的准确性各不相同,我们试图在我们的患者群体中确定它们的准确性。方法:选取2019年6月1日至2019年8月31日期间因疑似PE接受CTA检查的急诊科(ED)患者。两个cdts, Wells标准和修订后的Geneva评分,基于CTA之前的可用数据,并使用>500 μg/L的常见d -二聚体截止值计算。我们确定了PE与CDT值之间的关系,并确定了d -二聚体结果与PE之间的关系。结果:共发现cta 392例,PE阳性48例(12.1%)。Wells标准和修订后的Geneva评分与PE显著相关,但分别未能识别12.5%和70.4%的PE阳性病例。在我们的队列中,d -二聚体临界值>300 μg/L与PE显著相关,并捕获了95.2%的PE病例。结论:两种CDTs都与PE显著相关,但在大量病例中未能识别PE,尤其是修订后的日内瓦评分。可选的d -二聚体截止值在鉴别PE病例时可能提供更好的准确性。
{"title":"Effectiveness of Clinical Decision Tools in Predicting Pulmonary Embolism.","authors":"Michael A Simon,&nbsp;Christopher Tan,&nbsp;Patrick Hilden,&nbsp;Lyle Gesner,&nbsp;Barry Julius","doi":"10.1155/2021/8880893","DOIUrl":"https://doi.org/10.1155/2021/8880893","url":null,"abstract":"<p><strong>Objective: </strong>The Wells criteria and revised Geneva score are two commonly used clinical decision tools (CDTs) developed to assist physicians in determining when computed tomographic angiograms (CTAs) should be performed to evaluate the high index of suspicion for pulmonary embolism (PE). Studies have shown varied accuracy in these CDTs in identifying PE, and we sought to determine their accuracy within our patient population.</p><p><strong>Methods: </strong>Patients admitted to the Emergency Department (ED) who received a CTA for suspected PE from 2019 Jun 1 to 2019 Aug 31 were identified. Two CDTSs, the Wells criteria and revised Geneva score, were calculated based on data available prior to CTA and using the common D-Dimer cutoff of >500 <i>μ</i>g/L. We determined the association between confirmed PE and CDT values and determined the association between the D-Dimer result and PE.</p><p><strong>Results: </strong>392 CTAs were identified with 48 (12.1%) positive PE cases. The Wells criteria and revised Geneva score were significantly associated with PE but failed to identify 12.5% and 70.4% of positive PE cases, respectively. Within our cohort, a D-Dimer cutoff of >300 <i>μ</i>g/L was significantly associated with PE and captured 95.2% of PE cases.</p><p><strong>Conclusions: </strong>Both CDTs were significantly associated with PE but failed to identify PE in a significant number of cases, particularly the revised Geneva score. Alternative D-Dimer cutoffs may provide better accuracy in identifying PE cases.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2021 ","pages":"8880893"},"PeriodicalIF":4.3,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25451451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Prevalence of Latent Tuberculosis Infection in the Middle East and North Africa: A Systematic Review. 中东和北非地区肺结核潜伏感染率:系统回顾。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2021-01-28 eCollection Date: 2021-01-01 DOI: 10.1155/2021/6680651
Mazin Barry

Objective: Data on the prevalence of latent tuberculosis infection (LTBI) in Middle Eastern and North African countries are scarce. We aimed to review all relevant published data in countries belonging to this region to determine the overall prevalence of LTBI in the Middle East and North Africa (MENA) region.

Methods: In this systematic review PubMed and Google Scholar databases were searched for observational, prospective, retrospective, cross-sectional, and cohort studies providing prevalence data of LTBI in any MENA country. Studies fulfilling the search criteria were incorporated in the review. Overall prevalence of LTBI with 95% confidence intervals (CI) was calculated using the random-effects model; heterogeneity was assessed using I 2 statistics. Gender and age group-based subgroup analyses were performed to evaluate the basis of heterogeneity.

Results: The total number of overall LTBI studies identified was 956, of which 31 studies from ten countries within the MENA region were included that represented 12,439 subjects. The overall prevalence was 41.78% (95% CI 31.18% to 52.78%, I 2 = 99.31%). By gender-based subgroup analysis, the prevalence of LTBI was 33.12% (95% CI 18.97% to 49.04%, I 2 = 99.25%) and 32.65% (95% CI 19.79% to 47%, I 2 = 98.89%) in males and females, respectively, while in the age-based subgroup analysis, the prevalence of LTBI was 0.44% (95% CI -0.05% to 0.9%), 3.37% (95% CI 2.23% to 4.74%, I 2 = 0%), and 43.81% (95% CI 33.09% to 54.82%, I 2 = 99.18%) for children, adolescents, and adults, respectively.

Conclusion: This systematic review reveals a high prevalence of LTBI in the MENA region; enhanced LTBI surveillance and prompt infection prevention steps are urgently needed to prevent active tuberculosis, this would help achieve the World Health Organization End TB Strategy 2035, and the United Nations Sustainable Development Goals 2030 target in the MENA region.

目的:有关中东和北非国家肺结核潜伏感染率(LTBI)的数据很少。我们的目的是回顾该地区国家所有已发表的相关数据,以确定中东和北非地区(MENA)LTBI 的总体流行率:在这一系统性综述中,我们在 PubMed 和 Google Scholar 数据库中搜索了中东和北非国家中提供 LTBI 患病率数据的观察性、前瞻性、回顾性、横断面和队列研究。符合检索标准的研究被纳入综述。采用随机效应模型计算了LTBI的总体流行率及95%置信区间(CI);采用I 2统计量评估了异质性。为评估异质性的基础,还进行了基于性别和年龄组的亚组分析:已确定的 LTBI 研究总数为 956 项,其中包括来自中东和北非地区 10 个国家的 31 项研究,代表了 12,439 名受试者。总患病率为 41.78%(95% CI 31.18% 至 52.78%,I 2 = 99.31%)。通过基于性别的亚组分析,男性和女性的 LTBI 患病率分别为 33.12% (95% CI 18.97% to 49.04%, I 2 = 99.25%)和 32.65% (95% CI 19.79% to 47%, I 2 = 98.89%),而在基于年龄的亚组分析中,LTBI 患病率为 0.44%(95% CI -0.05%至0.9%)、3.37%(95% CI 2.23%至4.74%,I 2 = 0%)和43.81%(95% CI 33.09%至54.82%,I 2 = 99.18%):本系统综述揭示了中东和北非地区LTBI的高流行率;迫切需要加强LTBI监测并采取及时的感染预防措施来预防活动性结核病,这将有助于在中东和北非地区实现世界卫生组织2035年终结结核病战略和联合国2030年可持续发展目标。
{"title":"Prevalence of Latent Tuberculosis Infection in the Middle East and North Africa: A Systematic Review.","authors":"Mazin Barry","doi":"10.1155/2021/6680651","DOIUrl":"10.1155/2021/6680651","url":null,"abstract":"<p><strong>Objective: </strong>Data on the prevalence of latent tuberculosis infection (LTBI) in Middle Eastern and North African countries are scarce. We aimed to review all relevant published data in countries belonging to this region to determine the overall prevalence of LTBI in the Middle East and North Africa (MENA) region.</p><p><strong>Methods: </strong>In this systematic review PubMed and Google Scholar databases were searched for observational, prospective, retrospective, cross-sectional, and cohort studies providing prevalence data of LTBI in any MENA country. Studies fulfilling the search criteria were incorporated in the review. Overall prevalence of LTBI with 95% confidence intervals (CI) was calculated using the random-effects model; heterogeneity was assessed using <i>I</i> <sup>2</sup> statistics. Gender and age group-based subgroup analyses were performed to evaluate the basis of heterogeneity.</p><p><strong>Results: </strong>The total number of overall LTBI studies identified was 956, of which 31 studies from ten countries within the MENA region were included that represented 12,439 subjects. The overall prevalence was 41.78% (95% CI 31.18% to 52.78%, <i>I</i> <sup>2</sup> = 99.31%). By gender-based subgroup analysis, the prevalence of LTBI was 33.12% (95% CI 18.97% to 49.04%, <i>I</i> <sup>2</sup> = 99.25%) and 32.65% (95% CI 19.79% to 47%, <i>I</i> <sup>2</sup> = 98.89%) in males and females, respectively, while in the age-based subgroup analysis, the prevalence of LTBI was 0.44% (95% CI -0.05% to 0.9%), 3.37% (95% CI 2.23% to 4.74%, <i>I</i> <sup>2</sup> = 0%), and 43.81% (95% CI 33.09% to 54.82%, <i>I</i> <sup>2</sup> = 99.18%) for children, adolescents, and adults, respectively.</p><p><strong>Conclusion: </strong>This systematic review reveals a high prevalence of LTBI in the MENA region; enhanced LTBI surveillance and prompt infection prevention steps are urgently needed to prevent active tuberculosis, this would help achieve the World Health Organization End TB Strategy 2035, and the United Nations Sustainable Development Goals 2030 target in the MENA region.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2021 ","pages":"6680651"},"PeriodicalIF":2.0,"publicationDate":"2021-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25351259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Vitamin D Deficiency and Newly Diagnosed Pulmonary Tuberculosis. 维生素D缺乏与新诊断肺结核的关系。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2021-01-15 eCollection Date: 2021-01-01 DOI: 10.1155/2021/5285841
Vijay Jaimni, Barkur Ananthakrishna Shasty, Sharath P Madhyastha, Ganesh V Shetty, Raviraja V Acharya, Ragini Bekur, Akhila Doddamani

Introduction: Vitamin D has a significant role in host immune defense against Mycobacterium tuberculosis. It has been suggested that pulmonary tuberculosis may be associated with lower levels of vitamin D. Present study was therefore undertaken to identify the association between vitamin D deficiency and pulmonary tuberculosis.

Methods: A case-control study was conducted in a tertiary care hospital from 2014 to 2016, including 50 adult newly diagnosed sputum positive pulmonary tuberculosis patients as cases and 50 age and sex-matched healthy participants as control groups. All participants in the study group had undergone detailed clinical examination and routine laboratory investigations, including vitamin D, calcium, and sputum for AFB. The clinical characteristics, X-ray findings, sputum AFB, and vitamin D levels were analyzed and compared with data obtained from healthy controls.

Results: In both groups, the majority were men (88%). BMI was significantly (<0.0001∗) lower in the tuberculosis group (19.40 (17.20, 22.0) vs. 24.00 (22.50, 25.47)). Serum vitamin D levels were significantly lower (P = 0.012) in the tuberculosis group (19 (7.75, 27.25) ng/dl) as compared to the control group (25 (19.75, 32.00) ng/dl). Out of 50 TB patients, 27 (54%) had vitamin D deficiency, while among healthy controls, only 13 (26%) had vitamin D deficiency. Among vitamin D deficient PTB patients, 44% had 3+/hpf AFB in sputum smear examination.

Conclusion: The prevalence of vitamin D deficiency in pulmonary tuberculosis cases is very high. Hypovitaminosis D was associated with more severe clinical symptoms, higher sputum smear positivity, and extensive lesions in chest radiograph among pulmonary tuberculosis patients.

维生素D在宿主对结核分枝杆菌的免疫防御中具有重要作用。有人认为,肺结核可能与维生素D水平较低有关。因此,本研究旨在确定维生素D缺乏与肺结核之间的关系。方法:2014 - 2016年在某三级医院进行病例-对照研究,以50例成人新诊断痰阳性肺结核患者为病例,50例年龄和性别匹配的健康受试者为对照组。研究组的所有参与者都进行了详细的临床检查和常规实验室检查,包括维生素D、钙和AFB的痰。分析临床特征、x线表现、痰AFB和维生素D水平,并与健康对照者的数据进行比较。结果:两组患者中,男性占88%。结核病组BMI (19 (7.75, 27.25) ng/dl)显著高于对照组(25 (19.75,32.00)ng/dl) (P = 0.012)。在50名结核病患者中,27人(54%)缺乏维生素D,而在健康对照组中,只有13人(26%)缺乏维生素D。在维生素D缺乏的肺结核患者中,44%的患者痰涂片检查中有3+/hpf AFB。结论:维生素D缺乏症在肺结核患者中的患病率很高。维生素D缺乏症与肺结核患者临床症状更严重、痰涂片阳性较高、胸片病变广泛相关。
{"title":"Association of Vitamin D Deficiency and Newly Diagnosed Pulmonary Tuberculosis.","authors":"Vijay Jaimni,&nbsp;Barkur Ananthakrishna Shasty,&nbsp;Sharath P Madhyastha,&nbsp;Ganesh V Shetty,&nbsp;Raviraja V Acharya,&nbsp;Ragini Bekur,&nbsp;Akhila Doddamani","doi":"10.1155/2021/5285841","DOIUrl":"https://doi.org/10.1155/2021/5285841","url":null,"abstract":"<p><strong>Introduction: </strong>Vitamin D has a significant role in host immune defense against Mycobacterium tuberculosis. It has been suggested that pulmonary tuberculosis may be associated with lower levels of vitamin D. Present study was therefore undertaken to identify the association between vitamin D deficiency and pulmonary tuberculosis.</p><p><strong>Methods: </strong>A case-control study was conducted in a tertiary care hospital from 2014 to 2016, including 50 adult newly diagnosed sputum positive pulmonary tuberculosis patients as cases and 50 age and sex-matched healthy participants as control groups. All participants in the study group had undergone detailed clinical examination and routine laboratory investigations, including vitamin D, calcium, and sputum for AFB. The clinical characteristics, X-ray findings, sputum AFB, and vitamin D levels were analyzed and compared with data obtained from healthy controls.</p><p><strong>Results: </strong>In both groups, the majority were men (88%). BMI was significantly (<0.0001∗) lower in the tuberculosis group (19.40 (17.20, 22.0) vs. 24.00 (22.50, 25.47)). Serum vitamin D levels were significantly lower (<i>P</i> = 0.012) in the tuberculosis group (19 (7.75, 27.25) ng/dl) as compared to the control group (25 (19.75, 32.00) ng/dl). Out of 50 TB patients, 27 (54%) had vitamin D deficiency, while among healthy controls, only 13 (26%) had vitamin D deficiency. Among vitamin D deficient PTB patients, 44% had 3+/hpf AFB in sputum smear examination.</p><p><strong>Conclusion: </strong>The prevalence of vitamin D deficiency in pulmonary tuberculosis cases is very high. Hypovitaminosis D was associated with more severe clinical symptoms, higher sputum smear positivity, and extensive lesions in chest radiograph among pulmonary tuberculosis patients.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2021 ","pages":"5285841"},"PeriodicalIF":4.3,"publicationDate":"2021-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38878657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Safety and Feasibility of a Novel Protocol for Percutaneous Dilatational Tracheostomy in Patients with Respiratory Failure due to COVID-19 Infection: A Single Center Experience. 新方案经皮扩张性气管切开术治疗COVID-19感染呼吸衰竭患者的安全性和可行性:单中心经验
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2021-01-13 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8815925
Ziad Boujaoude, Nagendra Madisi, Bhavi Patel, Jean-Sebastien Rachoin, R Phillip Dellinger, Wissam Abouzgheib

Introduction: The rapidly spreading Novel Coronavirus 2019 (COVID-19) appeared to be a highly transmissible pathogen in healthcare environments and had resulted in a significant number of patients with respiratory failure requiring tracheostomy, an aerosol-generating procedure that places healthcare workers at high risk of contracting the infection. Instead of deferring or delaying the procedure, we developed and implemented a novel percutaneous dilatational tracheostomy (PDT) protocol aimed at minimizing the risk of transmission while maintaining favorable procedural outcome. Patients and Methods. All patients who underwent PDT per novel protocol were included in the study. The key element of the protocol was the use of apnea during the critical part of the insertion and upon any opening of the ventilator circuit. This was coupled with the use of enhanced personnel protection equipment (PPE) with a powered air-purifying respirator (PAPR). The operators underwent antibody serology testing and were evaluated for COVID-19 symptoms two weeks from the last procedure included in the study.

Results: Between March 12th and June 30th, 2020, a total of 32 patients underwent PDT per novel protocol. The majority (80%) were positive for COVID-19 at the time of the procedure. The success rate was 94%. Only one patient developed minor self-limited bleeding. None of the proceduralists developed positive serology or any symptoms compatible with COVID-19 infection.

Conclusion: A novel protocol that uses periods of apnea during opening of the ventilator circuit along with PAPR-enhanced PPE for PDT on COVID-19 patients appears to be effective and safe for patients and healthcare providers.

导言:快速传播的2019年新型冠状病毒(COVID-19)在医疗环境中似乎是一种高度传染性的病原体,并导致大量呼吸衰竭患者需要气管切开术,这是一种产生气溶胶的手术,使医护人员面临感染的高风险。我们没有推迟或推迟手术,而是开发并实施了一种新的经皮扩张性气管切开术(PDT)方案,旨在最大限度地降低传播风险,同时保持良好的手术结果。患者和方法。所有按照新方案接受PDT治疗的患者都被纳入研究。该方案的关键要素是在插入的关键部分和呼吸机回路的任何打开时使用呼吸暂停。此外,还使用了增强型人员防护装备(PPE)和动力空气净化呼吸器(PAPR)。操作人员接受抗体血清学检测,并在研究中最后一次手术后两周评估COVID-19症状。结果:在2020年3月12日至6月30日期间,共有32名患者接受了新方案的PDT治疗。大多数(80%)在手术时呈COVID-19阳性。成功率为94%。只有一名患者出现轻度自限性出血。未出现血清学阳性或与COVID-19感染相符的任何症状。结论:一种新的方案,在打开呼吸机回路期间使用呼吸暂停时间,并在COVID-19患者的PDT中使用papr增强的PPE,对患者和医疗保健提供者来说似乎是有效和安全的。
{"title":"Safety and Feasibility of a Novel Protocol for Percutaneous Dilatational Tracheostomy in Patients with Respiratory Failure due to COVID-19 Infection: A Single Center Experience.","authors":"Ziad Boujaoude,&nbsp;Nagendra Madisi,&nbsp;Bhavi Patel,&nbsp;Jean-Sebastien Rachoin,&nbsp;R Phillip Dellinger,&nbsp;Wissam Abouzgheib","doi":"10.1155/2021/8815925","DOIUrl":"https://doi.org/10.1155/2021/8815925","url":null,"abstract":"<p><strong>Introduction: </strong>The rapidly spreading Novel Coronavirus 2019 (COVID-19) appeared to be a highly transmissible pathogen in healthcare environments and had resulted in a significant number of patients with respiratory failure requiring tracheostomy, an aerosol-generating procedure that places healthcare workers at high risk of contracting the infection. Instead of deferring or delaying the procedure, we developed and implemented a novel percutaneous dilatational tracheostomy (PDT) protocol aimed at minimizing the risk of transmission while maintaining favorable procedural outcome. <i>Patients and Methods</i>. All patients who underwent PDT per novel protocol were included in the study. The key element of the protocol was the use of apnea during the critical part of the insertion and upon any opening of the ventilator circuit. This was coupled with the use of enhanced personnel protection equipment (PPE) with a powered air-purifying respirator (PAPR). The operators underwent antibody serology testing and were evaluated for COVID-19 symptoms two weeks from the last procedure included in the study.</p><p><strong>Results: </strong>Between March 12th and June 30th, 2020, a total of 32 patients underwent PDT per novel protocol. The majority (80%) were positive for COVID-19 at the time of the procedure. The success rate was 94%. Only one patient developed minor self-limited bleeding. None of the proceduralists developed positive serology or any symptoms compatible with COVID-19 infection.</p><p><strong>Conclusion: </strong>A novel protocol that uses periods of apnea during opening of the ventilator circuit along with PAPR-enhanced PPE for PDT on COVID-19 patients appears to be effective and safe for patients and healthcare providers.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2021 ","pages":"8815925"},"PeriodicalIF":4.3,"publicationDate":"2021-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38878658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma. 肺腺癌患者细胞学标本中EML4-ALK融合基因的流行。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2020-12-23 eCollection Date: 2020-01-01 DOI: 10.1155/2020/3578748
Didik S Heriyanto, Ika Trisnawati, Evan G Kumara, Vincent Laiman, Fara S Yuliani, Auliya S B Sumpono, Rita Cempaka, Marcellus, Eko Budiono

Background: Under the National Comprehensive Cancer Network (NCCN) guidelines for non-small-cell lung carcinoma (NSCLC), anaplastic lymphoma kinase (ALK) gene rearrangement is required to be assessed. However, data showing the prevalence of the ALK rearrangement is still deficient and is not yet available in Indonesia. This study used direct smear preparation from transthoracic needle specimens that are minimally invasive. The main objective of the study is to identify the prevalence of the ALK fusion rearrangement gene in cytological specimens.

Materials and methods: A total of 35 direct smear preparations diagnosed as lung adenocarcinoma and EGFR mutation negative were involved in this study. The samples were taken between 2017 and 2019. These samples were examined for EML4-ALK fusion rearrangement gene using qRT-PCR. The EML4-ALK rearrangement status was determined by qRT-PCR with high-resolution melting (HRM) analysis.

Results: A total of 28 (80%) samples were from males, and 7 samples were from females. Seven (20% 95% CI: 8.4%-36.9%) samples were EML4-ALK rearrangement positive. The average age of the patients was 63.5 years old. The most common sites of metastasis in this study were pleural cavity, bone, liver, and CNS.

Conclusions: qRT-PCR successfully identified EML4-ALK fusion rearrangement in direct smear preparations of lung adenocarcinoma. Direct smear samples can be used for EML4-ALK rearrangement detection using qRT-PCR. The EML4-ALK rearrangement gene has high prevalence in selected lung adenocarcinoma and EGFR mutation-negative populations. ALK inhibitors in lung cancer can be openly considered for use in Indonesian patients to improve the outcome of this subset of patients.

背景:根据国家综合癌症网络(NCCN)非小细胞肺癌(NSCLC)指南,间变性淋巴瘤激酶(ALK)基因重排需要进行评估。然而,显示ALK重排流行率的数据仍然不足,而且在印度尼西亚还没有数据。本研究采用微创经胸穿刺标本直接涂片制备。本研究的主要目的是确定ALK融合重排基因在细胞学标本中的流行程度。材料与方法:本研究共纳入35例诊断为肺腺癌且EGFR突变阴性的直接涂片制剂。这些样本是在2017年至2019年之间采集的。采用qRT-PCR检测EML4-ALK融合重排基因。采用高分辨率熔融(HRM) qRT-PCR检测EML4-ALK重排状态。结果:男性28份,占80%,女性7份。7例(20% 95% CI: 8.4% ~ 36.9%) EML4-ALK重排阳性。患者平均年龄63.5岁。本研究中最常见的转移部位为胸膜腔、骨、肝和中枢神经系统。结论:qRT-PCR成功鉴定了肺腺癌直接涂片制剂中EML4-ALK融合重排。直接涂片样品可用于qRT-PCR检测EML4-ALK重排。EML4-ALK重排基因在特定的肺腺癌和EGFR突变阴性人群中具有很高的患病率。可以公开考虑在印度尼西亚患者中使用ALK抑制剂来改善这部分患者的预后。
{"title":"The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma.","authors":"Didik S Heriyanto,&nbsp;Ika Trisnawati,&nbsp;Evan G Kumara,&nbsp;Vincent Laiman,&nbsp;Fara S Yuliani,&nbsp;Auliya S B Sumpono,&nbsp;Rita Cempaka,&nbsp;Marcellus,&nbsp;Eko Budiono","doi":"10.1155/2020/3578748","DOIUrl":"https://doi.org/10.1155/2020/3578748","url":null,"abstract":"<p><strong>Background: </strong>Under the National Comprehensive Cancer Network (NCCN) guidelines for non-small-cell lung carcinoma (NSCLC), anaplastic lymphoma kinase (ALK) gene rearrangement is required to be assessed. However, data showing the prevalence of the ALK rearrangement is still deficient and is not yet available in Indonesia. This study used direct smear preparation from transthoracic needle specimens that are minimally invasive. The main objective of the study is to identify the prevalence of the ALK fusion rearrangement gene in cytological specimens.</p><p><strong>Materials and methods: </strong>A total of 35 direct smear preparations diagnosed as lung adenocarcinoma and EGFR mutation negative were involved in this study. The samples were taken between 2017 and 2019. These samples were examined for EML4-ALK fusion rearrangement gene using qRT-PCR. The EML4-ALK rearrangement status was determined by qRT-PCR with high-resolution melting (HRM) analysis.</p><p><strong>Results: </strong>A total of 28 (80%) samples were from males, and 7 samples were from females. Seven (20% 95% CI: 8.4%-36.9%) samples were EML4-ALK rearrangement positive. The average age of the patients was 63.5 years old. The most common sites of metastasis in this study were pleural cavity, bone, liver, and CNS.</p><p><strong>Conclusions: </strong>qRT-PCR successfully identified EML4-ALK fusion rearrangement in direct smear preparations of lung adenocarcinoma. Direct smear samples can be used for EML4-ALK rearrangement detection using qRT-PCR. The EML4-ALK rearrangement gene has high prevalence in selected lung adenocarcinoma and EGFR mutation-negative populations. ALK inhibitors in lung cancer can be openly considered for use in Indonesian patients to improve the outcome of this subset of patients.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2020 ","pages":"3578748"},"PeriodicalIF":4.3,"publicationDate":"2020-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39151890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Role of the Bronchoalveolar Lavage in Noncritically Ill Patients during the SARS-CoV-2 Epidemic. SARS-CoV-2流行期间支气管肺泡灌洗在非危重患者中的作用
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2020-12-17 eCollection Date: 2020-01-01 DOI: 10.1155/2020/9012187
Olivier Taton, Emmanuelle Papleux, Benjamin Bondue, Christiane Knoop, Sébastien Van Laethem, Alain Bauler, Delphine Martiny, Isabel Montesinos, Marie-Luce Delforge, Kahina Elmaouhab, Dimitri Leduc

Background: Bronchoalveolar lavage (BAL) is currently not recommended in noncritically ill patients for the diagnosis of SARS-CoV-2 infection. Indeed, the diagnosis is based on the RT-PCR test on a nasopharyngeal swab (NPS) and abnormal findings on the chest CT scan. However, the sensitivity of the NPS and the specificity of the chest CT scan are low. Results of BAL in case of negative NPS testing are underreported, especially in the subgroup of immunocompromised patients.

Objectives: The added value of BAL in the management of unstable, but noncritically ill patients, suspected of having SARS-CoV-2 infection despite one previous negative NPS and the side effects of the procedure for the patients and the health-care providers, were assessed during the epidemic peak of the COVID-19 outbreak in Belgium.

Methods: This multicentric study included all consecutive noncritically ill patients hospitalized with a clinical and radiological suspicion of SARS-CoV-2 infection but with a negative NPS. BAL was performed according to a predefined decisional algorithm based on their state of immunocompetence, the chest CT scan features, and their respiratory status.

Results: Among the 55 patients included in the study, 14 patients were diagnosed with a SARS-CoV-2 infection. Interestingly, there was a relationship between the cycle threshold of the RT-PCR and the interval of time between the symptom onset and the BAL procedure (Pearson's correlation coefficient = 0.8, p = 0.0004). Therapeutic management was changed in 33 patients because another infectious agent was identified in 23 patients or because an alternative diagnosis was made in 10 patients. In immunocompromised patients, the impact of BAL was even more marked (change in therapy for 13/17 patients). No significant adverse event was noted for patients or health-care staff. All health-care workers remained negative for SARS-CoV-2 NPS and serology at the end of the study.

Conclusions: In this real-life study, BAL can be performed safely in selected noncritically ill patients suspected of SARS-CoV-2 infection, providing significant clinical benefits that outweigh the risks.

背景:支气管肺泡灌洗(BAL)目前不推荐用于非危重患者诊断SARS-CoV-2感染。事实上,诊断是基于鼻咽拭子(NPS)的RT-PCR测试和胸部CT扫描的异常发现。然而,NPS的敏感性和胸部CT扫描的特异性较低。在NPS检测阴性的情况下,BAL的结果被低估了,特别是在免疫功能低下的患者亚组中。目的:在比利时2019冠状病毒病暴发的流行高峰期间,评估BAL在管理疑似感染SARS-CoV-2的不稳定但非危重患者中的附加价值,以及该程序对患者和卫生保健提供者的副作用。方法:本多中心研究纳入了临床和影像学怀疑为SARS-CoV-2感染但NPS阴性的所有连续住院的非危重患者。基于免疫能力状态、胸部CT扫描特征和呼吸状态,根据预定义的决策算法进行BAL。结果:纳入研究的55例患者中,有14例患者被诊断为SARS-CoV-2感染。有趣的是,RT-PCR的周期阈值与症状出现和BAL手术之间的时间间隔之间存在相关性(Pearson相关系数= 0.8,p = 0.0004)。由于在23名患者中发现了另一种感染源或在10名患者中做出了替代诊断,33名患者的治疗管理发生了变化。在免疫功能低下的患者中,BAL的影响更为明显(13/17的患者改变了治疗方法)。未发现患者或卫生保健人员发生重大不良事件。在研究结束时,所有卫生保健工作者的SARS-CoV-2 NPS和血清学检测均为阴性。结论:在这项现实生活中的研究中,BAL可以安全地用于疑似SARS-CoV-2感染的非危重患者,提供了显著的临床益处,超过了风险。
{"title":"Role of the Bronchoalveolar Lavage in Noncritically Ill Patients during the SARS-CoV-2 Epidemic.","authors":"Olivier Taton,&nbsp;Emmanuelle Papleux,&nbsp;Benjamin Bondue,&nbsp;Christiane Knoop,&nbsp;Sébastien Van Laethem,&nbsp;Alain Bauler,&nbsp;Delphine Martiny,&nbsp;Isabel Montesinos,&nbsp;Marie-Luce Delforge,&nbsp;Kahina Elmaouhab,&nbsp;Dimitri Leduc","doi":"10.1155/2020/9012187","DOIUrl":"https://doi.org/10.1155/2020/9012187","url":null,"abstract":"<p><strong>Background: </strong>Bronchoalveolar lavage (BAL) is currently not recommended in noncritically ill patients for the diagnosis of SARS-CoV-2 infection. Indeed, the diagnosis is based on the RT-PCR test on a nasopharyngeal swab (NPS) and abnormal findings on the chest CT scan. However, the sensitivity of the NPS and the specificity of the chest CT scan are low. Results of BAL in case of negative NPS testing are underreported, especially in the subgroup of immunocompromised patients.</p><p><strong>Objectives: </strong>The added value of BAL in the management of unstable, but noncritically ill patients, suspected of having SARS-CoV-2 infection despite one previous negative NPS and the side effects of the procedure for the patients and the health-care providers, were assessed during the epidemic peak of the COVID-19 outbreak in Belgium.</p><p><strong>Methods: </strong>This multicentric study included all consecutive noncritically ill patients hospitalized with a clinical and radiological suspicion of SARS-CoV-2 infection but with a negative NPS. BAL was performed according to a predefined decisional algorithm based on their state of immunocompetence, the chest CT scan features, and their respiratory status.</p><p><strong>Results: </strong>Among the 55 patients included in the study, 14 patients were diagnosed with a SARS-CoV-2 infection. Interestingly, there was a relationship between the cycle threshold of the RT-PCR and the interval of time between the symptom onset and the BAL procedure (Pearson's correlation coefficient = 0.8, <i>p</i> = 0.0004). Therapeutic management was changed in 33 patients because another infectious agent was identified in 23 patients or because an alternative diagnosis was made in 10 patients. In immunocompromised patients, the impact of BAL was even more marked (change in therapy for 13/17 patients). No significant adverse event was noted for patients or health-care staff. All health-care workers remained negative for SARS-CoV-2 NPS and serology at the end of the study.</p><p><strong>Conclusions: </strong>In this real-life study, BAL can be performed safely in selected noncritically ill patients suspected of SARS-CoV-2 infection, providing significant clinical benefits that outweigh the risks.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2020 ","pages":"9012187"},"PeriodicalIF":4.3,"publicationDate":"2020-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9012187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38767731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Corrigendum to "Patient Delay in Initiating Tuberculosis Treatment and Associated Factors in Oromia Special Zone, Amhara Region". “阿姆哈拉地区奥罗米亚特区患者延迟开始结核病治疗及其相关因素”的更正。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2020-11-10 eCollection Date: 2020-01-01 DOI: 10.1155/2020/9505083
Muhammed Abdu, Awraris Balchut, Eshetu Girma, Wondwosen Mebratu

[This corrects the article DOI: 10.1155/2020/6726798.].

[这更正了文章DOI: 10.1155/2020/6726798。]
{"title":"Corrigendum to \"Patient Delay in Initiating Tuberculosis Treatment and Associated Factors in Oromia Special Zone, Amhara Region\".","authors":"Muhammed Abdu,&nbsp;Awraris Balchut,&nbsp;Eshetu Girma,&nbsp;Wondwosen Mebratu","doi":"10.1155/2020/9505083","DOIUrl":"https://doi.org/10.1155/2020/9505083","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2020/6726798.].</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2020 ","pages":"9505083"},"PeriodicalIF":4.3,"publicationDate":"2020-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9505083","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38736730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutrophil Oxidized-Modified Proteins and Neutrophil Extracellular Traps in Patients with Community-Acquired Pneumonia. 社区获得性肺炎患者中性粒细胞氧化修饰蛋白和中性粒细胞胞外陷阱。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2020-09-15 eCollection Date: 2020-01-01 DOI: 10.1155/2020/4897038
Vilen Molotov-Luchanskiy, Altynbek Nukhuly, Larissa Muravlyova, Ryszhan Bakirova, Aruna Kossybayeva, Dmitry Klyuyev, Ludmila Demidchik, Irina Beinikova

Materials and methods: 51 patients with CAP were divided into 2 groups depending on the severity of the pathological process. The first group (I) consisted of 32 patients with moderate severity of pneumonia. The second group (II) consisted of 19 patients with severe pneumonia. The third group (III), the comparison group, consisted of 14 CAP patients with chronic obstructive pulmonary disease (COPD). The control group consisted of 19 volunteers.

Results: Statistically significant increase in the level of carbonyl derivatives (CD) in patients of all study groups relative to the control group was revealed. In the group of patients with moderate severity and severe pneumonia, also in CAP patients with COPD, the level of CD exceeded the control group. There was no statistically significant difference in the level of advanced oxidation protein products (AOPP) and myeloperoxidase (MPO) in blood neutrophils between the studied groups.

Conclusion: Results indicate an oxidative imbalance in neutrophils and contribute to the worsening of the course of the disease.

材料与方法:51例CAP患者根据病理过程的严重程度分为两组。第一组(I)包括32例中度肺炎患者。第二组(II) 19例重症肺炎患者。第三组(III)为对照组,14例CAP合并慢性阻塞性肺疾病(COPD)患者。对照组由19名志愿者组成。结果:与对照组相比,各研究组患者的羰基衍生物(CD)水平均有统计学意义的升高。在中、重度肺炎患者组以及CAP合并COPD患者中,CD水平均超过对照组。两组患者血液中性粒细胞中高级氧化蛋白产物(AOPP)和髓过氧化物酶(MPO)水平差异无统计学意义。结论:结果提示中性粒细胞氧化失衡,导致病程恶化。
{"title":"Neutrophil Oxidized-Modified Proteins and Neutrophil Extracellular Traps in Patients with Community-Acquired Pneumonia.","authors":"Vilen Molotov-Luchanskiy,&nbsp;Altynbek Nukhuly,&nbsp;Larissa Muravlyova,&nbsp;Ryszhan Bakirova,&nbsp;Aruna Kossybayeva,&nbsp;Dmitry Klyuyev,&nbsp;Ludmila Demidchik,&nbsp;Irina Beinikova","doi":"10.1155/2020/4897038","DOIUrl":"https://doi.org/10.1155/2020/4897038","url":null,"abstract":"<p><strong>Materials and methods: </strong>51 patients with CAP were divided into 2 groups depending on the severity of the pathological process. The first group (I) consisted of 32 patients with moderate severity of pneumonia. The second group (II) consisted of 19 patients with severe pneumonia. The third group (III), the comparison group, consisted of 14 CAP patients with chronic obstructive pulmonary disease (COPD). The control group consisted of 19 volunteers.</p><p><strong>Results: </strong>Statistically significant increase in the level of carbonyl derivatives (CD) in patients of all study groups relative to the control group was revealed. In the group of patients with moderate severity and severe pneumonia, also in CAP patients with COPD, the level of CD exceeded the control group. There was no statistically significant difference in the level of advanced oxidation protein products (AOPP) and myeloperoxidase (MPO) in blood neutrophils between the studied groups.</p><p><strong>Conclusion: </strong>Results indicate an oxidative imbalance in neutrophils and contribute to the worsening of the course of the disease.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2020 ","pages":"4897038"},"PeriodicalIF":4.3,"publicationDate":"2020-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/4897038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38453475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pulmonary Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1